Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY)
| Market Cap | 8.37B -7.2% |
| Revenue (ttm) | 39.43B +3.0% |
| Net Income | 792.98M +40.2% |
| EPS | 0.21 +41.6% |
| Shares Out | n/a |
| PE Ratio | 10.55 |
| Forward PE | 11.51 |
| Dividend | 0.20 (2.84%) |
| Ex-Dividend Date | Dec 31, 2025 |
| Volume | n/a |
| Average Volume | 568 |
| Open | 7.07 |
| Previous Close | 7.07 |
| Day's Range | 7.07 - 7.07 |
| 52-Week Range | 6.39 - 8.32 |
| Beta | 0.35 |
| RSI | 43.10 |
| Earnings Date | Mar 31, 2026 |
About SHPMY
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as in... [Read more]
Financial Performance
In 2024, SHPMY's revenue was 275.25 billion, an increase of 5.75% compared to the previous year's 260.30 billion. Earnings were 4.55 billion, an increase of 20.82%.
Financial numbers in CNY Financial StatementsNews
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...